PCART 3 - MediSix Therapeutics
Alternative Names: PCART-3Latest Information Update: 20 Mar 2023
Price :
$50 *
At a glance
- Originator MediSix Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
Most Recent Events
- 17 Mar 2023 Preclinical trials in Cutaneous T-cell lymphoma in Singapore (Parenteral) (MediSix Therapeutics pipeline, March 2023)
- 13 Jan 2023 Preclinical trial in Peripheral T-cell lymphoma in Singapore (Parenteral) (MediSix Therapeutics pipeline, January 2023)